Cogstate Limited

ASX CGS.AX

Cogstate Limited Net Cash Used For Investing Activities for the year ending June 30, 2024: USD -1.12 M

Cogstate Limited Net Cash Used For Investing Activities is USD -1.12 M for the year ending June 30, 2024, a 48.92% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Cogstate Limited Net Cash Used For Investing Activities for the year ending June 30, 2023 was USD -2.19 M, a 35.47% change year over year.
  • Cogstate Limited Net Cash Used For Investing Activities for the year ending June 30, 2022 was USD -3.39 M, a -28.54% change year over year.
  • Cogstate Limited Net Cash Used For Investing Activities for the year ending June 30, 2021 was USD -2.64 M, a 9.94% change year over year.
  • Cogstate Limited Net Cash Used For Investing Activities for the year ending June 30, 2020 was USD -2.93 M, a -22.20% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
SV Wall Street
ASX: CGS.AX

Cogstate Limited

CEO Mr. Bradley John O'Connor B.Bus, C.A., CA
IPO Date Feb. 12, 2004
Location Australia
Headquarters 161 Collins Street
Employees 160
Sector Healthcare
Industries
Clinical Trials Biotechnology Medical Instruments Mental Health Telehealth
Description

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.

Similar companies

PWH.AX

PWR Holdings Limited

USD 5.22

1.36%

StockViz Staff

February 7, 2025

Any question? Send us an email